Konzentrat zur Herstellung einer Infusionslösung Carboplatin
Sponsors
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Services Unlimited Company, Bristol Myers Squibb International Corporation, Janssen - Cilag International
Conditions
Early Stage Non-Small Cell Lung Cancer (NSCLC)Locally Advanced or Metastatic Non-Small Cell Lung CancerPreviously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)Resectable Stage II-IIIB Non-small cell lung cancer
Phase 3
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)
CompletedCTIS2022-502886-71-00
Start: 2019-11-20End: 2024-05-31Target: 485Updated: 2024-05-20
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet
Chemotherapy in Early Stage NSCLC
CompletedCTIS2022-501360-18-00
Start: 2017-03-15End: 2024-12-03Target: 194Updated: 2024-12-03
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (CheckMate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 77T)
Active, not recruitingCTIS2022-502658-15-00
Start: 2019-09-22Target: 252Updated: 2025-10-08
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in
Combination with Platinum-Based Chemotherapy Compared with Platinum-Based
Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-
Small Cell Lung Cancer After Osimertinib Failure
Active, not recruitingCTIS2023-506518-33-00
Start: 2021-11-10Target: 259Updated: 2025-11-13